RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$45.77
−3.95%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.19x
- Price / sales
- 109.80x
- Price / cash flow
- -22.71x
Enterprise value
- Enterprise value
- $1.8B
- EV / sales
- 88.50x
- EV / EBITDA
- -11.95x
- EV / EBIT
- -11.53x
- Market cap
- $2.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026